IN2012DN00624A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00624A
IN2012DN00624A IN624DEN2012A IN2012DN00624A IN 2012DN00624 A IN2012DN00624 A IN 2012DN00624A IN 624DEN2012 A IN624DEN2012 A IN 624DEN2012A IN 2012DN00624 A IN2012DN00624 A IN 2012DN00624A
Authority
IN
India
Prior art keywords
fatigue
treatments
diseases
prevention
compositions
Prior art date
Application number
Other languages
English (en)
Inventor
Moise A Khayrallah
Gary Bream
Stephen E Butts
Susan Marie Melnick
Duncan Taylor
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of IN2012DN00624A publication Critical patent/IN2012DN00624A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
IN624DEN2012 2009-06-22 2010-06-21 IN2012DN00624A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21908209P 2009-06-22 2009-06-22
PCT/US2010/039313 WO2011005473A2 (fr) 2009-06-22 2010-06-21 Procédés de traitement ou de prévention de la fatigue

Publications (1)

Publication Number Publication Date
IN2012DN00624A true IN2012DN00624A (fr) 2015-06-12

Family

ID=43429751

Family Applications (1)

Application Number Title Priority Date Filing Date
IN624DEN2012 IN2012DN00624A (fr) 2009-06-22 2010-06-21

Country Status (13)

Country Link
US (5) US8741950B2 (fr)
EP (1) EP2445490B1 (fr)
JP (3) JP6095366B2 (fr)
KR (3) KR20120098578A (fr)
CN (2) CN102481274A (fr)
AU (1) AU2010270971B2 (fr)
BR (1) BRPI1015233A2 (fr)
CA (1) CA2765463C (fr)
IN (1) IN2012DN00624A (fr)
MX (1) MX2012000034A (fr)
RU (1) RU2567801C2 (fr)
TW (1) TWI453014B (fr)
WO (1) WO2011005473A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1890684B1 (fr) 2005-06-08 2013-08-14 SK Biopharmaceuticals Co., Ltd. Traitement de troubles du cycle sommeil-éveil
US8741950B2 (en) 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
JP5836280B2 (ja) 2009-11-06 2015-12-24 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥/多動性障害(adhd)の治療方法
CA2779442A1 (fr) * 2009-11-06 2011-05-12 Sk Biopharmaceuticals Co., Ltd. Procedes pour traiter un syndrome de fibromyalgie
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
WO2013096423A1 (fr) * 2011-12-21 2013-06-27 Herbal Powers Corporation Thérapie combinée par un interféron et des andrographolides destinés à la sclérose en plaques
SG11201507121RA (en) 2013-03-13 2015-10-29 Aerial Biopharma Llc Treatment of cataplexy
KR20160030955A (ko) * 2013-07-12 2016-03-21 에스케이바이오팜 주식회사 금연의 촉진
DK3021838T3 (da) * 2013-07-18 2020-08-24 Jazz Pharmaceuticals Ireland Ltd Behandling af fedme
ES2777250T3 (es) * 2013-11-08 2020-08-04 Legacy Healthcare Ltd Método para el tratamiento del cáncer y las enfermedades concomitantes del cáncer
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
FI3509582T3 (fi) 2016-09-06 2024-02-08 Axsome Malta Ltd (r)-2-amino-3-fenyylipropyylikarbamaatin solvaattimuoto
SG11201903076QA (en) 2016-10-06 2019-05-30 Jazz Pharmaceuticals International Iii Ltd Carbamoyl phenylalaninol compounds and uses therof
CN111201014A (zh) 2017-06-02 2020-05-26 爱尔兰贾兹制药有限公司 治疗过度嗜睡的方法和组合物
CN111094238B (zh) 2017-07-31 2023-06-09 杰资制药爱尔兰有限公司 氨基甲酰基苯丙氨醇类似物及其用途
JP7428480B2 (ja) * 2019-06-06 2024-02-06 雪印メグミルク株式会社 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
WO2023091921A1 (fr) * 2021-11-16 2023-05-25 Axsome Malta Ltd. Méthodes et compositions pour le traitement d'une déficience cognitive

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA943862B (en) 1993-06-10 1995-12-04 Lilly Co Eli Method of preventing emesis and treating sexual dysfunction using tetrahydrobenz[cd] indole-6-carboxamides
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
WO1998015626A2 (fr) 1996-10-08 1998-04-16 Institute Of Child Health Molecule mutante ciita et ses utilisations
PT873308E (pt) * 1996-10-10 2002-06-28 Sk Corp Compostos de o-carbamoil-fenilalaninol seus sais farmaceuticamente uteis e processo para a preparacao dos mesmos
WO1998017636A1 (fr) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Derives de phenylalaninol pour le traitement de troubles du systeme nerveux central
US20040229951A1 (en) 2003-05-15 2004-11-18 Arthur Vanmoor Method of treating fatigue by enhancing the effectiveness of the human immune system
RU2267319C2 (ru) * 2003-07-15 2006-01-10 Общество с ограниченной ответственностью "Интер-Кэр" Фармацевтическая композиция и способ лечения синдрома хронической усталости с ее использованием
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
AU2005302589B2 (en) * 2004-10-28 2010-09-16 Sk Biopharmaceuticals Co., Ltd. Adjunctive therapy for depression
EP1890684B1 (fr) 2005-06-08 2013-08-14 SK Biopharmaceuticals Co., Ltd. Traitement de troubles du cycle sommeil-éveil
KR101335942B1 (ko) 2005-06-22 2013-12-04 에스케이바이오팜 주식회사 성기능 장애의 치료
WO2007018496A1 (fr) 2005-07-26 2007-02-15 Janssen Pharmaceutica, N.V. Procédés pour traiter des troubles liés à des substances
EP2079449A2 (fr) 2006-10-13 2009-07-22 Janssen Pharmaceutica, N.V. Compositions de phénylalkylaminocarbamate
US8741950B2 (en) * 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
CA2779442A1 (fr) 2009-11-06 2011-05-12 Sk Biopharmaceuticals Co., Ltd. Procedes pour traiter un syndrome de fibromyalgie
JP5836280B2 (ja) 2009-11-06 2015-12-24 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥/多動性障害(adhd)の治療方法
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
SG11201507121RA (en) * 2013-03-13 2015-10-29 Aerial Biopharma Llc Treatment of cataplexy
JP6215740B2 (ja) * 2014-03-14 2017-10-18 本田技研工業株式会社 部品の締結構造

Also Published As

Publication number Publication date
US10507192B2 (en) 2019-12-17
US9464041B2 (en) 2016-10-11
JP2018188450A (ja) 2018-11-29
EP2445490A4 (fr) 2019-10-23
CA2765463A1 (fr) 2011-01-13
EP2445490B1 (fr) 2023-02-08
WO2011005473A9 (fr) 2011-05-12
CA2765463C (fr) 2018-10-09
US20140243406A1 (en) 2014-08-28
CN102481274A (zh) 2012-05-30
TW201105320A (en) 2011-02-16
JP2015214564A (ja) 2015-12-03
MX2012000034A (es) 2012-02-21
US20180263950A1 (en) 2018-09-20
JP2012530779A (ja) 2012-12-06
US20120142769A1 (en) 2012-06-07
TWI453014B (zh) 2014-09-21
CN106727486A (zh) 2017-05-31
KR20170086710A (ko) 2017-07-26
RU2012101947A (ru) 2013-07-27
EP2445490A2 (fr) 2012-05-02
AU2010270971B2 (en) 2015-08-20
RU2567801C2 (ru) 2015-11-10
US8741950B2 (en) 2014-06-03
JP6368285B2 (ja) 2018-08-01
US20170000756A1 (en) 2017-01-05
US20200061017A1 (en) 2020-02-27
AU2010270971A1 (en) 2012-01-19
WO2011005473A2 (fr) 2011-01-13
JP6095366B2 (ja) 2017-03-15
KR20190105675A (ko) 2019-09-17
US9999609B2 (en) 2018-06-19
BRPI1015233A2 (pt) 2018-02-20
KR102173587B1 (ko) 2020-11-04
KR102021075B1 (ko) 2019-11-04
KR20120098578A (ko) 2012-09-05

Similar Documents

Publication Publication Date Title
IN2012DN00624A (fr)
IN2012DN03883A (fr)
MX351464B (es) El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas.
EP2493464A4 (fr) Méthylsulfonylméthane (msm) pour le traitement de micro-organismes résistants aux médicaments
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MY173616A (en) Compositions and methods for lowering triglycerides
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
EP2294184A4 (fr) Traitement de maladies oculaires et d une néovascularisation excessive utilisant un traitement combiné
MX2011007930A (es) Conjugados de insulina cristalina.
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
AU2011338383A8 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
MY161495A (en) Virus like particle compositions and methods of use
IN2012DN02081A (fr)
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
TN2011000482A1 (en) Organic compounds and their uses
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
EA201001639A1 (ru) Композиции и способы их получения и применения
IN2012DN02471A (fr)
TNSN08400A1 (en) Organic compounds and their uses
MY178905A (en) Prevention, treatment and diagnosis of p.gingivalis infection
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
MX342947B (es) Tratamiento de diabetes tipo 2.
WO2013098416A3 (fr) Composes anti-douleur